Article

David W. Parke II, MD, named president of American Academy of Ophthalmology

San Francisco-As of Jan. 1, David W. Parke II, MD, assumed the role of president of the American Academy of Ophthalmology (AAO).

San Francisco-As of Jan. 1, David W. Parke II, MD, assumed the role of president of the American Academy of Ophthalmology (AAO), taking over from the departing president C.P. Wilkinson, MD. Dr. Parke's other leadership roles include the Edward L. Gaylord professor, chairman of the Department of Ophthalmology at the University of Oklahoma, and chief executive officer of the Dean A. McGee Eye Institute, Oklahoma City, OK.

"There has never been a more exciting time for ophthalmology as medical advances give ophthalmologists breakthrough treatment options to save vision," said Dr. Parke. "Ophthalmology is also faced with challenges ranging from Medicare reimbursement to scope of practice. I look forward to serving the academy and its members in the year ahead."

Dr. Parke has held several positions with the AAO. He has served on the academy's board of trustees since 2000, as trustee-at-large from 2000 to 2001, and as senior secretary for ophthalmic practice from 2002 to 2006. Academy committees he has served on include the instruction advisory committee, nominating committee, awards committee, and bylaws and rules committee.

"Few leaders come to this presidency post with this much experience and dedication to the Academy and the profession," said H. Dunbar Hoskins Jr., MD, executive vice president of the academy. "We are thrilled to have Dr. Parke lead us through this year."

Dr. Parke achieved his medical degree at Baylor College of Medicine in Houston and completed his residency at the Cullen Eye Institute, followed by a fellowship in medical retina and a subsequent fellowship in surgical retina.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.